Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon gamma-1b + sargramostim
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Interferon gamma-1b + sargramostim is a combination of two recombinant cytokine biologics being investigated as an adjuvant immunotherapy for pulmonary Mycobacterium avium complex (MAC) and other nontuberculous mycobacterial (NTM) lung infections. Interferon gamma-1b (brand name Actimmune) is a recombinant form of interferon gamma that activates macrophages through the interferon-gamma receptor, enhancing their bactericidal activity and ability to clear intracellular pathogens. Sargramostim (brand name Leukine) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production, differentiation, and activation of macrophages and other myeloid cells via the GM-CSF receptor. The combination is designed to address immune dysregulation in patients with chronic NTM infections by boosting macrophage-mediated clearance of the bacteria, particularly in cases where standard multi-drug antibiotic therapy has failed.
- Brand names
- Actimmune + Leukine
- Other names
- interferon gamma + granulocyte-macrophage colony-stimulating factorIFN-gamma + GM-CSFinterferon gamma-1b + GM-CSFadjuvant cytokine therapy
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on interferon gamma-1b + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon gamma-1b + sargramostim.